The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD) Meeting Abstract
| Authors: | Krieger, L.; Shapiro, J.; Byard, I.; Campbell, D.; Clay, T.; Ganju, V.; Watkins, S.; Simmons, A.; Go, J.; Shetty, S.; Golsorkhi, T.; Abida, W.; Ryan, C. J.; Scher, H. I.; Chowdhury, S. |
| Abstract Title: | The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD) |
| Meeting Title: | COSA's 44th Annual Scientific Meeting |
| Journal Title: | Asia-Pacific Journal of Clinical Oncology |
| Volume: | 13 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2017 Nov 13-15 |
| Meeting Location: | Sydney, Australia |
| ISSN: | 1743-7555 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2017-11-01 |
| Start Page: | 164 |
| Language: | English |
| ACCESSION: | WOS:000413954500256 |
| PROVIDER: | wos |
| PUBMED: | 29082610 |
| DOI: | 10.1111/ajco.12799 |
| Notes: | Meeting Abstract: 263 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
